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INTRODUCTION 
Diabetic ketoacidosis (DKA) is one of the most common medical 
emergencies in the World.The patient may present with wide range of 
manifestations like ketosis, ketoacidosis, ketoacidosis pre- coma and 
coma1, but often these manifestations are submerged in the clinical 
presentation of precipitating illnesses. Even though it is more common in 
type 1 diabetes mellitus it occurs in type 2 diabetes also, especially in 
certain situations like infections and other co- morbid illnesses2. Recent 
advances have been made in early detection and treatment of both 
ketoacidosis and the co- morbidities so as to make changes in the natural  
history of this illness. 
Diabetic ketoacidosis is an acute complication of diabetes wherein 
there is hyperglycaemia, ketosis and metabolic acidosis3. Ketoacidosis is 
the presence of ketones in blood or urine with pH < 7.3 ,blood 
bicarbonate< 20mmol/L, and anion gap >16meq/L.  
In diabetic ketoacidosis, Beta-hydroxybutyrate is synthesized at a 
threefold greater rate than acetoacetate4. However, acetoacetate is the 
ketone body detected by the nitroprusside test. Earlier diagnosis is  
possible only with detection of capillary Beta-hydroxybutyrate over 
acetoacetate in urine. 
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Serum or plasma assays for Beta-hydroxybutyrate are preferred 
since they  reflect the true ketone body levels. Resolution of diabetic 
ketoacidosis is also better reflected with the measurement of capillary 
hydroxybutyrate. As DKA is physiologically always preceded by the 
production of ketone bodies (i.e. acetoacetate and 3β-hydroxybutyrate), 
strategies aiming at reducing the occurrence of ketosis events may have a 
direct impact on the global reduction of DKA incidence.  
Measurement of capillary Beta-hydroxybutyrate eliminates the 
problem of false negatives and false positives (with Captopril, NAC, 
Penicillamine) seen in the traditional approach.  
Early identification of diabeticketoacidosis helps to decrease 
morbidity and mortality.Therefore alternate diagnostic tests to detect 
ketone bodies should be employed for early identification and early 
initiation of treatment. Hence the need for this study. 
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AIMS AND OBJECTIVES OF  THE STUDY 
1. To detect ketone bodies by the two methods; urine acetoacetic acid 
and capillary beta hydroxybutyrate to diagnose diabetic 
ketoacidosis. 
2. To compare the two methods in early diagnosis and management of 
diabetic ketoacidosis  
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REVIEW  OF LITERATURE 
HISTORICAL  BACK GROUND  
Clinical descriptions of polyuric states resembling diabetes mellitus 
have been described in the Ebers papyrus of Egypt in 15th century BC5,6 . 
Ayurvedic literature from the times of Charaka and Sushrutha, the  
ancient  Indian physicians identified two forms of “Madhu Meha” 
(honeyed Urine) in 400 BC5 . One is associated with gluttony, obese build 
and indolence and the other is characterized  by  thin  build  and  early  
mortality  recognized  by  these intuitive sages. 
Important land marks in the history of diabetes and  DKA 
In 17th Century Thomas Willis of England5,7 , observed  that  some 
patient’s Urine contain Sugar. John Rolo5 of England in 1797 was  one of 
1st who coined the term diabetes mellitus. In 18th Century Mathew 
Dobson7 of England found that diabetic Serum Contain Sugar William 
Prout8 of England described diabetic coma during 1810–20. Langerhans 
of Germany identified Pancreatic Islets in 1869. Adolf Kussmaul9 of 
Germany  observed acidotic breathing in diabetic coma patient.In 1907, 
Jean de Mayer of Belgium postulated hypothetical glucose lowering 
hormone  named  insulin. In  1922  Banting9 ,  Best, Collip and Macleod 
isolated and clinically used insulin and later won Nobel prize for that 
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memorable invention. F.Sanger of England did sequencing of insulin and 
Roth et al. discovered insulin receptors in 1971.  In 1977, Ulrich et al 
cloned insulin gene. In 1984 human recombinant Insulin was available 
for clinical use and human insulin analogues in the year  200110. 
Incidence and mortality 
                     It is the commonest cause of death among patients with type 
1 diabetes below 20 years of age11. DKA can occur both in type 1 and 
type 2 diabetes patients. It accounts for 8%–29% of all hospital 
admissions of patients with diabetes as the primary diagnosis with 
average mortality rates of 5%–10%, and as high as 15% in the elderly 
population12.  The  prognosis substantially worsened at  the extremes of 
age. Prior to the discovery of  insulin by  Banting &  Best in  1922, the 
mortality rate associated with episodes of  DKA was almost 100%11 .  By 
1932 the mortality rate among 1007 patients with  DKA  reported  by 
Bertram10 from a review of 25 different authors was down to 29%. It 
accounts for 8%–29% of all hospital admissions of patients with diabetes 
as the primary diagnosis with average mortality rates of 5%–10%, and as 
high as 15% in the elderly population12.This decline  reflects  the  
introduction of  antibiotic therapy in  the   mid 1940s as well as 
improvements in patient care, prompt therapy,observation, appropriate 
use of fluid and insulin brought down the mortality in 1950s.   Recent  
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reports  of  National  Institute  of  Health  (NIH)  data  analysis 13 
suggests that between 1969 and 1973 the mortality rate for DKA in the 
patients with diabetes was 10%. After that the mortality rate steadily 
decreased and became 4- 5%. It is mainly due to the immediate attention 
given to the patient in the emergency  room. 
DEFINITIONS OF DIABETIC KETOACIDOSIS 
One of greatest pitfalls in reporting on the incidence, 
epidemiology, and mortality rate for DKA has been the lack of a 
uniformly accepted definition . The syndrome consists of the triad of 
hyperglycemia,  ketosis,  and  acidemia,14  each  of  which  may  
independently be associated with other clinical conditions. The consensus 
among most workers in this field is that an arterial pH of less than 7.3, a  
bicarbonate value of less than 15 mEq/L, and a blood glucose level of 
greater than 250 mg/dl, with a moderate degree of ketonemia and 
ketonuria (as determined by the nitroprusside method) are necessary for 
the diagnosis. 
 It is important  to  note  that  although  the  majority of patients 
with DKA arrives at the emergency room already received insulin and /or 
a  reduction in food intake, both of which can contribute  to reduced 
plasma glucose concentrations, while the remaining parameters still show 
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a moderate degree of metabolic decompensation. Alterations in blood 
glucose values may also be due to variations in hydration or due to 
reduction in   the concentration of counterregulatory hormones such as 
glucagons and catecholamines, particularly in patients with longstanding 
diabetes .  Therefore blood glucose levels should not be a primary factor 
in  determining the severity of  DKA. 
PRECIPITATING FACTORS FOR DKA15 
Inadequate insulin treatment or non-compliance  
Patients on insulin pumps have an increased risk of DKA secondary to 
pump dysfunction 
New onset diabetes (20-25%) 
Acute illness- Infection (30-40%), cerebrovascular accident, myocardial 
infarction, acute pancreatitis 
Drugs- Clozapine or olanzapine, cocaine, thiazide diuretics, terbutaline, 
corticosteroids and dobutamine 
Trauma, surgery 
Rarely DKA maybe the primary manifestation of acromegaly and 
cushing’s disease. 
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TAB:1 - CAUSES OF DIABETIC KETOACIDOSIS   
 
 
PATHOGENESIS : 
1. Disturbance in  intermediary metabolism 
2. Disturbance in fluid, electrolyte, and acid- base   balance 
INTERMEDIARY METABOLISM 
             In DKA there is severe alterations in the metabolism of 
carbohydrate, protein, and lipid  due to lack of insulin with  concomitant 
elevation of counter regulatory hormones such as glucagons, 
catecholamines and cortisol. So hyperglycemia and lipolysis play central 
roles  in the formation of  DKA. 
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The major insulin- sensitive tissues in the human body are liver, 
muscle and fat in contrast to the glucose metabolism in nervous system 
(Brain), a  prototype of  insulin independent tissue, as  originally 
described by  Cahill16 .  Brain cells, as it is an insulin- insensitive 
tissue,they continue to use glucose as the main fuel,  even  during  food  
deprivation and starvation, as well as during diabetic ketoacidosis.Hence 
glucose supply to  the  brain is essential for mentation.  
The insulin sensitive tissues like fat, liver and muscle forego the 
use of glucose during starvation, stress or DKA. This  change in 
intermediary metabolism is brought about both by lack of effective 
insulin and by increase in the levels of counter regulatory hormones like 
glucagon. 
Catecholamines, in the absence of effective insulin, promotes 
lipolysis to free fatty acids (FFA) and glycerol, the later providing carbon 
skeleton and the former reducing equivalents for gluconeogenesis, 
glucose production from non- carbohydrate precursors. Gluconeogenesis 
is specifically stimulated as a result of increased glucagon and decreased 
insulin levels, which results in stimulation of,phosphoenol pyruvate 
carboxy kinase (PEPCK),  the rate limiting enzyme  of  gluconeogenesis.  
So hyperglycemia is brought about primarily by increased 
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gluconeogenesis, accelerated conversion of glycogen to glucose 
(Glycogenolysis) and by inadequate utilization of glucose by peripheral 
tissues due to insulin deficiency. The later is further exaggerated  by  
increased levels of  circulating catecholamines17 . 
Fig.1 : Proposed biochemical changes that occur during diabetic 
ketoacidosis 
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KETO ACID PRODUCTION  : 
The beta- oxidation of the accumulated FFA leads to increased  
ketone bodies formation and converts FFA to very low – density 
lipoprotein (VLDL) in the liver. Severe hypertriglyceridemia is seen 
clinically as lipemia retinalis. Ketogenesis is  further enhanced by  
decreased concentrations  of malonyl coenzyme- A which occurs as a 
result of the increased ratio of glucagons to insulin levels in DKA. 
Malonyl COA inhibits carnitine palmitoyl  acyl transferase (CPT1), the 
rate limiting enzyme of ketogenesis18 . There is a shift of insulin sensitive 
tissues governing the intermediary metabolism from a carbohydrate 
metabolizing systems which is prevalent in the fed state to a fat 
metabolizing system in diabetic  ketoacidosis. 
Increased hepatic ketone body production and decreased  
peripheral  tissue metabolism lead to acetoacetate accumulation in the 
blood18. A small fraction undergoes spontaneous decarboxylation to form 
acetone, but the majority is converted to ß hydroxybutyrate. The relative 
proportions in which three ketone bodies namely acetoacetate, acetone  
and  ß  hydroxybutyrate present in blood vary depending on the redox 
state  of  the  cell.  In healthy people ß hydroxybutyrate and acetoacetate, 
which are present at approximately equimolar concentrations, constitute 
virtually all ketones19 .  
 
 
12  
 
FIG 2 :Pathophysiology of DiabeticKetoAcidosis 
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FIG 3 PATHOGENESIS OF DIABETIC KETOACIDOSIS 
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FLUID AND ELECTROLYTE LOSSES AND METABOLIC  
ACIDOSIS: 
The  major cause of  fluid loss in  DKA  is  osmotic  diuresis which 
causes excess excretion of  glucose in  the urine. This leads to  osmotic 
diuresis resulting in sodium, chloride and  potassium  excretion  in  the  
urine  in  large  amounts accompanied by severe water  loss. 
Table – 2: Typical total body deficits of water and electrolytes in 
DKA  
Total water   (in litre) 6 litres 
Sodium (mEq / kg) 100 
Chloride (mEq / kg) 7- 10 
Potassium (mEq / kg) 3- 5 
Phosphate (mol/kg) 5- 7 
Magnesium (mEq / kg) 1- 2 
Calcium (mEq / kg) 1- 2 
 Amount of fluid and sodium chloride deficits per kilogram of body 
weight in DKA include 100 ml of water, 7- 10 mEq of sodium and  5- 7  
mEq  of  chloride,which corresponds to approximately 10% body weight 
dehydration.In DKA, glucose is restricted  to  the  extra  cellular  space 
driving water from the intracellular to the extracellular   compartment. 
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Thus initially the intracellular fluid volume decreases with an 
associated dilution of the plasma sodium concentration. Subsequently, 
hyperglycemia  brings osmotic diuresis with losses of water and sodium 
chloride in the urine, with water losses exceeding sodium chloride losses. 
Ultimately the fluid losses from  the intracellular and extracellular 
compartments are quantitatively  similar. Because of the osmotic shift of 
water, plasma sodium concentrations are frequently low or normal in 
DKA despite extensive water losses.  
              The plasma sodium concentrations in this setting can be corrected 
to what it would be if hyperglycemia were corrected by adding 1.6 mEq to 
the reported sodium value for every 100 mg of glucose over 100  mg/dl21 .  
severe hyperlipidemia lowers plasma sodium factiously because the 
elevated levels of lipid displace plasma water and resulting in incorrect 
calculation of sodium values.  
POTASSIUM DEPLETION : 
There is profound depletion of potassium in DKA.  The deficit can 
be from   5- 10 mEq / kg body weight to 10 mEq/kg. Despite profound 
potassium  depletion, plasma potassium concentrations are typically 
normal or elevated at the time of presentation with DKA22 . The presence 
of hyper osmolality in the extracellular fluid shifts water and potassium 
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from the intracellular to extra cellular space. This potassium shift is  
further  enhanced  by  the  presence of acidosisresulting in the breakdown 
of intracellular protein. Further more entry of potassium into the cells is 
diminished by insulin deficiency.  The  net  result of  these multiple 
factors is  a  marked change in  the internal balance of potassium, shifting 
potassium from the intracellular to extracellular space22. 
 Excessive urinary potassium  losses causes potassium  depletion  as  
a   result  of  effects  of   osmotic diuresis leading to increased delivery of 
fluid and sodium to potassium secretory sites in the  distal nephrons.  
Secondary hyperaldosteronism23  related  to sodium depletion and the 
presence of negatively charged ketoanions in the tubular fluid further 
enhance urinary potassium losses24 . These factors alter the external 
balance of potassium which causes potassium losses  greater  than the 
potassium intake. 
METABOLIC ACIDOSIS 
The acidosis in DKA is due to enhanced production  of ketoacids  
which  fully  dissociate  at  physiologic  pH.  The  H+  ions are buffered 
by both extra cellular (primarily H ion) and intracellular buffers,which 
results in metabolic   acidosis.The  retention   of    ketoacids  
(acetoacetate   and    ß hydroxybutyrate)  results in an increase in the 
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plasma anion gap, which is in the majority of patients with DKA is 
quantitatively similar to the decrease in plasma bicarbonate 
concentration. Ketoanions are reabsorbed with ranging 75% to 85%25 by 
the kidneys. Therefore excretion of ketonebodies in urine occurs during 
enhanced ketoacid production as in DKA, because of the difference 
between the quantity of ketoacids filtered compared with the amount 
reabsorbed.  
 Glucose and ketoanion excretion in the  urine depends on 
glomerular filtration rate. Progressive volume depletion leads to 
decreased glomerular filtration rate. So greater degree of volume 
depletion causes  greater retention of glucose and ketoanions in plasma. 
So patients rescuscitated earlier with fluids have better preservation of 
renal function and greatest ketoanion excretion resulting in  lower  
plasma ketoanion concentrations and lower plasma anion gap.During 
treatment with insulin, hydrogen ions are consumed  as ketoanion 
metabolism is facilitated. This therefore,  contributes  to  regeneration of 
bicarbonate with correction of metabolic acidosis and to a decrease in 
plasma anion gap. Hence, the urinary loss of ketoanions represents the 
loss of potential  bicarbonate26 . 
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Table 3 :   Differential Diagnosis of Ketosis and Anion Gap  Acidosis 
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FIG 4 : SYMPTOM COMPLEX IN DKA 
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Table 4 : Clinical &  Laboratory characteristics of  DKA   versus 
HHNKS (Hype rglycemic hyperosmolar nonketotic state18 
No Variables DKA HHNKS 
1. Age. Younger Older 
2. Respiration 
Hyperventilation, 
deep. 
Normal, 
shallow. 
3. Dehydration 
Moderate to 
severe 
Severe 
4. Consciousness Diminished Comatose 
5. Urine Ketone > 3+ < 1+ 
6. Plasma glucose (mg/dl) > 250 >600 
7. Serum sodium(mEq/ L) 130-140 145 – 155 
8. S.potassium(mEq/L) 3- 6 3- 5 
9. Serum HCO3  (mEq/L) <15 > 20 
10. Blood urea (mg/dl) 42- 70 60- 180 
11. Peptide (nm) 0.21 1.14 
12. Serum osmolality Variable > 330 MOsm/kg 
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Table – 5 : Manifestations of diabetic   ketoacidosis 
Manifestations of DKA 
Symptoms 
            Physical findings Signs 
Nausea Tachycardia, Dry mucous  membrane 
Vomiting Dehydration, Reduced skin turgor, 
Thirst Hypotension, Kussmaul respiration 
Polyuria Tachypnea,Respiratory distress 
Abdominal pain Obtundation , Abdominal tenderness 
Shortness of breath Cerebral edema, Coma. 
 
Table –  6 :   Diagnostic criteria for DKA28 
Variables Mild Moderate Severe HHS 
Plasma glucose (mg/dl) > 250 > 250 > 250 > 600 
Arterial pH 7.25- 7.3 7.24- 7.1 < 7 > 7.3 
Serum bicarbonate (mEq/L) 15- 18 10- 15 < 10 > 15 
Urine ketones by 
nitroprusside method 
Positive Positive Positive Small 
Serum ketones Positive Positive Positive Small 
Effective serum osmolality 
(m Osm/kg) 
Variable Variable Variable > 320 
Anion gap > 10 > 12 > 12 Variable 
Alteration in sensorium or 
mental obtundation 
Alert Alert/drowsy Stupor/Cons Stupor/cons 
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INVESTIGATIONS OF DIABETIC KETOACIDOSIS 
Laboratory investigations for diabetic ketoacidosis should be scheduled 
as 
 Serum glucose every 1-2 hourly till the patient is stable and 
thereafter every 4-6 th hourly. 
 Serum electrolyte estimation every 1-2 hourly till the patient is 
stable and thereafter every 4-6 th hourly 
 Initial Blood urea nitrogen 
 Initial Arterial Blood Gas analysis followed with bicarbonate . 
Laboratory tests like potassium ,glucose ,electrolytes and if needed 
phosphorous should be repeated. High serum glucose level may lead to 
dilutional hyponatremia and high triglyceride levels may lead to low 
glucose levels.High levels of ketone bodies may cause false elevation of 
creatinine levels. 
Plasma Glucose Study 
Blood glucose level is usually greater than 250 mg /dl in patients 
with diabetic ketoacidosis.Fingerstick blood glucose test can also be 
peformed while waiting for the plasma glucose level. 
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TESTING FOR KETONES 
URINE KETONES  
Urine ketone tests are difficult because of the nature of ketone 
bodies (3β-hydroxybutyrate versus acetoacetate), the methods used for 
measurement, and the kinetics of ketone production and clearance.  
           Although the production of 3β-hydroxybutyrate and acetoacetate is 
equimolar in the human blood, situations like DKA favor the 
accumulation of 3β-hydroxybutyrate, with levels reaching up to 10 times 
those of acetoacetate 29. Also, changes in mitochondrial redox state after 
DKA stimulate the conversion of 3β-hydroxybutyrate to acetoacetate, 
which then accumulates in the urine30, whereas blood 3β-hydroxybutyrate 
levels decrease quickly (half-life of ≈90 minutes) after insulin injection. 
The commonly used methods for the detection of ketone bodies in 
serum or urine  doesnot react with all 3 ketone bodies. Gerhardt’s ferric 
chloride test reacts with acetoacetate only. Nitroprusside test is 10 times 
more sensitive to acetoacetate than to acetone and it doesnot react with 
beta hydroxybutyrate. So, most of the tests for ketosis detects 
acetoacetate only.  
               Traditional tests for beta hydroxybutyrate are indirect; they 
require brief boiling of the urine to remove acetone and acetoacetate by 
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evaporation (acetoacetate first break down spontaneously to acetone) 
followed by gentle oxidation of beta hydroxybutyrate to acetoacetate and 
acetone with peroxide, ferric ions or dichromate.  The acetoacetate thus 
formed may be detected with Gerhardt’s test or one of the procedures 
using Nitroprusside.  
The three ketone bodies are acetone (2%), acetoacetic acid (20%) 
and 3-β-hydroxybutyrate (78%). Thus increased hepatic ketone 
production and decreased peripheral tissue metabolism lead to 
acetoacetate accumulation in the blood. A major fraction is converted to 
β-hydroxybutyrate. In healthy people beta hydroxybutyrate and 
acetoacetate are present at equimolar concentrations, here acetone is 
minor component. In severe diabetes the ratio between beta 
hydroxybutyrate to acetoacetate may increase to 6: 1 owing to the 
presence of large concentration of NADH which favors beta 
hydroxybutyrate production. 
Method 
1. Rothera's test for acetone. 
2. Gerhard's test for diacetic acid 
3. Lindeman's test for diacetic acid 
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4. Han’s method for betahydroxybutyric acid. 
5. Tablet test 
Principle of Rotheras test                                                                         
Nitroprusside used in this test reacts with both acetone and 
acetoacetic acid in presence of alkali (NH4OH) to produce permanganent 
calomel red ring at the junction. 
 In DKA patients urine dipstick test is highly positive for glucose 
and ketones.Rarely it is negative for ketones since most of the available 
laboratory tests can detect only acetoacetate whereas the predominant 
ketone in severe untreated DKA is betahydroxybutyrate. 
BLOODKETONES 
The process of ketone production in DKA involves the formation 
of serum free fatty acids, which are used for the production of large 
quantities of ketone bodies (acetoacetate, β-hydroxybutyrate (β-OHB), 
and acetone), and consequent metabolic acidosis 31. While the liver is the 
site of ketone formation, the first ketone body produced is acetoacetic 
acid, which is reduced to β-OHB or acetone32. Therefore, the β-OHB to 
acetoacetate ratio, which is 1:1 in its normal state, is usually elevated to at 
least 3:1 in diabetic ketoacidosis at presentation33 and may be as much as 
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10:134 . β-OHB levels are the most abundant in the blood in DKA, 
representing 75% of total ketones formed35. 
 The blood β-OHB levels measured by reagent strips 
(ketostix,Labstix) and serum ketone levels by nitroprusside reaction are 
effective equally in diagnosing uncomplicated DKA. 
 Blood  β-OHB levels below 0.6 mmol/L are regarded as normal, 
while levels over 1 mmol/L represent hyperketonemia, and levels in 
excess of 3 mmol/L indicate ketoacidosis35   
The use of capillary β-OHB testing is more accurate than urinary 
ketone testing and compares well with the enzymatic method. This 
approach will be useful in early identification of DKA.  
BLOOD GAS ANALYSIS  
  In patients with DKA arterial blood gases frequently show typical 
manifestations of metabolic acidosis,low bicarbonate and low 
Ph.Response to treatment can be monitored by venous blood rather than 
arterial blood in blood gas analysers ,except where respiratory problems 
preclude using arterial blood36.. 
Although 15 to 20 years ago serum blood pH was routinely 
determined via an arterial blood gas sample, research has convincingly 
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shown that pH obtained by VBG is equally accurate, easier to obtain, and 
less painful for patients.Despite this advancement, diagnosing DKA has 
required at least two distinct blood tests: VBG for pH and serum 
chemistry for electrolytes. Furthermore, the turnaround time for a VBG is 
approximately 15 minutes compared with the 1-hour turnaround time for 
serum chemistry analysis, possibly allowing clinicians to make more 
rapid therapeutic decisions. 
SERUM ELECTROLYTES 
Serum potassium levels are high initially in DKA patients.It is due 
to extracellular shift of potassium in exchange of hydrogen , which gets 
accumulated in acidosis ,inspite of severe total body potassium 
depletion.so potassium levels has to be checked frequently as it drops 
rapidly with treatment.ECG is needed to assess the cardiac effects of 
extremes in potassium. 
Serum sodium levels are low in DKA patients, due to osmotic 
effect of hyperglycemia which moves the extravascular water to the 
intravascular space.When glucose level increases by 100mg/dl ,serum 
sodium level is lowered by 1.6 mEq/L and viceversa. 
Serum chloride levels and phosphorous levels are also low. 
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BICARBONATE 
Bicarbonate levels along with anion gap is used to assess the 
degree of acidosis . 
PHOSPHATE, CALCIUM , AND MAGNESIUM  
Serum phosphorous levels should be determined if the patient is at 
risk of hypophosphatemia due to chronic alcoholism or poor nutritional 
status. 
ANION GAP 
Anion gap is elevated (Na+K)-(Cl+HCO3) greater than 10 mEq/L 
in mild cases and greater than 12 mEq/L in moderate and severe cases. 
COMPLETE BLOOD COUNT 
Increased white blood cell count is seen in patients with Diabetic 
Ketoacidosis.Higher counts (>15 ×109) or marked left shift indicates 
underlying infection. 
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RENAL FUNCTION TESTS 
Blood urea Nitrogen is increased in DKA patients. 
PLASMA OSMOLARITY 
Plasma Osmolarity(>290 mOsm/L) and urine Osmolarity are 
increased in DkA patients.Plasma Osmolality can be calculated from the 
formula 2(Na+K) + BUN/3 + glucose /18.DKA patients with coma 
typically  have osmolalities greater than 330 mOsm/kg H2O .If it is less 
,other causes of coma should be evaluated. 
URINE AND BLOOD CULTURE  
It helps to identify possible infecting organisms in DKA patients 
AMYLASE  
Even in the absence of pancreatitis hyperamylasemia may be seen. 
CHEST RADIOGRAPHY 
Chest Xray is used to rule out infections like pneumonia. 
MRI 
It is helpful in detecting early cerebral edema ,if altered 
consciousness is present. 
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CT SCAN 
         In Dka child with altered mental status ,the threshold should be 
lowered as it may cause cerebral edema.In paediatric cases with 
suspected cerebral edema, hypertonic saline or mannitol should not be 
delayed as many of the changes are seen late on head imaging. 
ELECTROCARDIOGRAPHY 
         DKA may cause cardiac complications or it may be precipitated by 
a cardiac event.so ECG should be performed every 6 hours during the 
first day.ECG is crucial in detecting acute myocardial infarction which 
could be painless in diabetic patients with autonomic neuropathy. 
         Hyperkalemia and hypokalemia can be detected with peaked Twave 
and low T wave / U wave respectively. 
MANAGEMENT OF DKA: 
The cornerstones of management of DKA   are: 
1. Rehydration with intravenous  fluids 
2. Insulin administration 
3. Replacement of electrolytes 
4. General medical care 
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5. Treatment of precipitating causes 
6. Identification and treatment of  complications 
7. Complete educational programme 
8. Followupcare  
REHYDRATION: Fluid therapy 
DKA patients are  invariably dehydrated and  sodium chloride 
depleted.  So restoration of fluid and electrolytes deficits is the first 
priority. Initial fluid therapy should consist of isotonic saline because this 
fluid is restricted to the extracellular fluid space and more rapidly corrects 
plasma volume  than hypotonic fluid administration. In patients 
presenting with hypovolemic shock, colloid administration should also  
be  considered because colloids are retained exclusively  in  the  
intravascular  space37. In  addition  to  the  usual   physical 
examination findings to evaluate volume deficit, the corrected plasma 
sodium concentration  and   the   calculated  total   plasma  osmolality  
can   be  used   to estimate the severity of dehydration. Total plasma 
osmolality can be calculated by the following equation38 . 
2  x  Na+  (mEq/L) + Glucose (mg/dL) +  BUN (mg /  dL) 
    18      2.8 
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Corrected plasma sodium concentrations more than 140 mEq/L or 
calculated total osmolalities of greater than 340 m Osm/kg H2 O39 are 
associated with the largest fluid deficits. Calculated total osmolality 
correlates inversely with mental status examination, with stupor and coma 
typically seen with osmolalities of greater than 340 m Osm / kg H2 O.  
After the  initial  extra   cellular space expansion with isotonic 
saline, subsequent fluid therapy is administered as hypotonic saline 
(0.45% NaCl) at 200 - 1000 ml/ Hour depending on the state of hydration. 
Water losses exceed NaCl  loss  in  DKA,  with approximately equal water 
loss from  both  the  intracellular  and extracellular spaces.  The 
administration of  hypotonic saline, which is  similar  to the fluid loss 
during osmotic diuresis, leads to gradual replacement of both 
compartments. Dextrose should be added to intra venous fluids when 
blood glucose concentration is less than 200 mg / dL to allow continued 
insulin administration until ketonemia is controlled, while avoiding the 
complication of hypoglycemia.  
           Administration of fluid before insulin therapy does not alter  the  
severity of metabolic acidosis but does lead to significant reductions in 
Blood Urea   Nitrogen   (BUN)   and    in   glucose   and    potassium    
concentrations Aggressive early rehydration will restore normal 
circulatory volume. Rehydration alone lowers blood glucose 
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concentrations, primarily by augmenting glucose excretion with urine as 
well as by dilution in the extracellular space. Studies using this regimen of 
hydration  with one  litre of  0.9% NaCl in  the first hour followed by  
insulin and hydration    in more than 200 patients with DKA resulted in 
less than 0.5% mortality40 . The initial rate of  fluid replacement depends 
on  the underlying cardiac status and  the degree of volume depletion. 
Normally 15- 20 ml / kg/ hour (1- 1.5 litre in an average adult) is given in 
the 1st  hour to expand rapidly the intravascular space. 
Table-7:   Suggested replacement fluids41 
Time Volume 
1st hour 1- 2 L of normal saline 
2nd hour 1 L normal  saline 
3rd hour 500 ml   normal saline 
4th  hour 500 ml   normal or half normal  
saline 
5th  hour 500 ml   normal or half normal  
saline 
Total first 5    hours 3.5 to 5  L 
6th  –  12th hour 250 –  500 ml half normal saline  
hourly 
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INSULIN THERAPY: 
The primary goals of insulin therapy are to reverse  ketogenesis,  
prevent  lipolysis,  and   inhibit  hepatic    gluconeogenesis. Insulin also 
decreases the effective plasma osmolality by increasing cellular 
permeability to glucose. 
Insulin therapy should  not  be  initiated  in  patients with 
hypotension and severe hyperglycemia until  fluid replacement  has 
occurred  to  correct  hypovolemia.    Insulin  enhances  intracellular  
transport of glucose with a resultant fluid shift from the extracellular to 
the intracellular compartments. As much as 2- 3 litres of water may shift 
out of the intravascular compartment, increasing the risk of  hypovolemic 
shock and thromboembolism  in the setting of inadequate volume 
replacement.  
Insulin also mediates the re- entry of potassium into the 
intracellular compartment, insulin administration can lead to life- 
threatening hypokalemia, and should also be withheld in  patients who  
are  hypokalemic at  presentation (potassium less   than3.5mEq/L) until 
potassium replacement therapy is given . Insulin therapy in these 
situations may result in arrythmias, impaired cardiovascular function or 
muscle  weakness  and  respiratory  failure.  Ultimately, it is adequacy of 
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fluid and electrolyte repletion that determines the effectiveness of insulin  
therapy. 
During DKA there is usually profound insulin resistance requiring 
supraphysiologic doses of insulin to prevent ketogenesis, 
gluconeogenesis, and lipolysis and resolution of hyperglycemia and hyper 
osmolality42 .  
Intra venous administration is the preferred initial route of 
administration because  it  leads to   a    more   rapid   initial   fall   in   
glucose  and ketones   when   compared    with subcutaneous or 
intramuscular administration43 . After the first two hours of treatment, the 
rate of decline of ketonemia and hyperglycemia is comparable between 
all three routes of administration. IV administration offers the 
advantages44 ,  however, in  that it  can  be  titrated rapidly to  avoid 
hypoglycemia and is delivered more reliably in the setting of poor tissue 
perfusion or dehydration. 
  Before initiation of IV insulin, it  is suggested that about 50 ml of 
the insulin–saline solution be allowed to flow through the tubing to 
minimize subsequent insulin binding to the tubing during therapy. An 
initial loading dose of 0.15 U/kg (usually 10 units in adults) of regular 
insulin is followed by a continuous infusion at a rate of 0.1 U/ kg/hr 
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(usually 5- 10 U /  hr  in  adults)45 . This results in supraphysiologic 
serum insulin concentrations, which are adequate to suppress ketogenesis, 
lipolysis and gluconeogenesis. As sensitivity  to insulin decreases with 
increasing age, older patients tend to  require  more insulin during the 
acute management of hyperglycemia. The rate of IV insulin infusion must 
be reassessed and adjusted frequently based on the rate of change  of 
serum glucose concentrations. Insulin should not be stopped unless 
hypoglycemia occurs, in which case it should be  stopped  temporarily  
and  restarted  when patients are euglycemic again.  Dextrose should be 
added to the IV fluids  to maintain a blood glucose level between 120 and 
180   mg/ dl. 
In some centre it  is  difficult  to  administer  IV  infusion  of  
insulin.  In such cases other routes of administration may be used. Even 
in this setting an initial dose may be given intravenously, as the dose of 
0.15 U/ kg followed by subcutaneous  or  intramuscular  insulin  at  0.1U  
/kg  and  titrated  to decrease glucose by approximately 100 mg / dl / 
hour. 
 When regular insulin is used, intramuscular administration leads 
to faster peak insulin levels and less risk of hypoglycemia when 
compared with subcutaneous delivery with the newer rapid acting insulin 
analogues46 .   Subcutaneous administration also leads rapid peak but 
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without the risk of myonecrosis inherent to  intramuscular  
administration. The efficacy of subcutaneous rapid  acting  insulin  has  
been found to be comparable with regular IV insulin in    this setting. 
In a recent preliminary study, the treatment of mild and moderate 
DKA with hourly injections of subcutaneous lispro47  insulin was as  
effective as  the  use of a standard IV regular insulin protocol. The mean 
time of treatment to  correct  hyperglycemia  and   ketoacidosis  was   
similar  between    subcutaneous lispro and IV infusion of regular insulin.       
Treatment with subcutaneous insulin injections on an hourly schedule, 
however, may be difficult in most institutions because of the intensity of 
the treatment and the shortage of nursing staff on regular wards. 
Subcutaneous insulin analogs used as bolus,  hourly  or  two  hourly are 
as safe and effective as the treatment with IV regular insulin48 . 
 The rate of decline of blood glucose concentration and the mean duration 
of  treatment until correction of ketoacidosis were similar  among 
different treatment groups. No significant differences in the length of 
hospital stay, total amount of insulin administration until resolution of 
hyperglycemia or ketoacidosis, or the number  of  hypoglycemic events 
among  treatment groups. 
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1. In a conscious patient, the initial “priming” dose of insulin should 
be  based on body weight (Between 0.3 to 0.4  units  /  kg).  Half  
of  this should be given as IV bolus and IM or subcutaneous.   The 
effectiveness   of intramuscular and subcutaneous administration  is  
essentially  the same. However subcutaneous injection is easier, 
less painful, and less susceptible to cause tissue  necrosis. 
2. Subsequent insulin therapy depends to a large extent on  the 
location of  the patient and availability of resources. If the patient is 
in emergency room, infusion of 7  units per hour of IV insulin is    
appropriate. 
3. If the patient is on  a  general hospital ward,  hourly injections of  
insulin by subcutaneous routes are preferred. This ensures that the  
patient is  seen by the nursing staff on an hourly   basis. 
4. If the patient is in the ICU or step- down unit, however 7 units of 
insulin  per hour by continuous IV infusion is preferred. 
Intermittent or hourly bolus of low- dose IV insulin is not preferred 
because of short half –  life  of insulin. 
Criteria for resolution49 of DKA includes a glucose less than 
200 mg/dl, serum bicarbonate > 18 mEq/L and a venous pH of > 7.3.  
Once  DKA  is  resolved, if the patient is nil per orally continue IV 
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insulin and  fluid replacement and  supplement with  subcutaneous 
regular insulin as  needed every  4 hour. This can be given in 5- unit 
increments for every 50 mg / dl increase in blood glucose above 150 
mg/ dl upto 20  units for blood glucose of  >  300  mg  /  dl.  When 
the patient is  able to  eat, multiple  –  dose schedule should be  
started that uses a combination of short – or rapid acting and 
intermediate – or long – acting insulin as needed to control plasma  
glucose.  Continue  IV  insulin  infusion for 1- 2 h after the split- 
mixed regimen is begun to ensure adequate plasma insulin levels. An 
abrupt discontinuation of IV insulin coupled with a delayed onset of a 
subcutaneous insulin regimen may lead to worsened control; 
therefore, some overlap should occur in IV insulin therapy and 
initiation of subcutaneous insulin regimen.   
In patients with newly diagnosed diabetes, the initial total 
insulin dose should be 0.5 to 1 units / kg/ day divided into at least two 
doses in a regimen including short and long acting insulin until an 
optimal dose  is  established. Finally diabetes patients may be 
discharged on insulin and later anti hyperglycemic agent and life style  
modifications. 
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POTASSIUM THERAPY: 
Holler50 first recognized the importance of potassium repletion 
in the treatment of DKA. Before his publication, DKA patients used 
to  die  after apparent treatment and resolution of diabetic coma. 
Some patients after considerable hours of therapy and improvement 
suddenly fail rapidly and die. The urine sugar and ketone had cleared 
up. Potassium is important for muscle function, and hypokalemia, has 
been associated with arrythmias,   cardiac   arrest,   cardiovascular  
collapse,   muscle   weakness and respiratory failure. Potassium is 
predominantly an intracellular cation however increased extracellular 
hyperosmolality secondary to hyperglycemia  causes  a shift of water 
and potassium from the intracellular to the extracellular compartment. 
This potassium shift is enhanced by  insulin deficiency, acidosis  and 
accelerated breakdown of intracellular proteins.  
Osmotic  diuresis, secondary hyper aldosteronism, and urinary 
ketoanion excretion (in the form of potassium salts) leads to increased 
urinary potassium losses. With the administration of fluids and 
insulin there is typically a rapid decline in plasma potassium 
concentration as potassium shifts back into the cells. To prevent 
hypokalemia, potassium supplementation is begun if the serum 
potassium concentration is less than 5.5 mEq/L. Potassium should 
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initially be withheld in patients with anuria, acute renal failure or 
potassium above 5.5 mg/L. Usually   20- 30 mEq of potassium in 
each liter of fluid is sufficient to maintain plasma potassium levels 
between 4 and 5. Potassium can be supplemented as either potassium 
chloride or potassium phosphate the later to avoid excessive chloride 
administration and to prevent  severe  hypophosphatemia51.If  the  
patient  present with significant hypokalemia, potassium replacement 
should begin with fluid therapy and insulin treatment should be 
delayed until potassium concentration is restored to > 3.3 mEq/ L to 
avoid arrythmias or  cardiac arrest  and respiratory muscle weakness . 
Table-8 :   Guidelines for potassium  replacement52 
Serum K (mEq/L) Additional K in IV  fluids 
<3.5 40 mEq/L 
3.5 – 4.5 20 mEq /  L 
4.5 – 5.5 10 mEq /  L 
> 5.5 Stop potassium infusions 
 
 
Potassium should not be given if the patient is  anuric or  serum 
potassium in more than 5.5 mEq /    L. 
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BICARBONATE SUPPLEMENTATION: 
At  a  pH  more than 7, re- establishing insulin activity blocks 
lipolysis and resolves ketoacidosis without any added bicarbonate. Most 
modern investigators  are against routine bicarbonate use. In a scholarly 
review of  the  subject analyzing  the risks and benefits of bicarbonate 
therapy, Matz53 concluded that perhaps the only clear indication for use 
of bicarbonate in DKA is life- threatening hyperkalemia. Most patients 
with DKA already have a total body deficit of potassium even though the 
initial serum potassium may be high. The administration of bicarbonate 
will accelerate the decline in sodium potassium level, sometimes with 
disastrous consequences. In a retrospective analysis of 95 episodes  of  
severe   DKA,   Lever   E,  Jaspan54  detected   no   differences  in 
biochemical or clinical end points between episodes of DKA  treated  
with  sodium bicarbonate and not treated with sodium bicarbonate.   
Moris55 et al in a prospective randomized study, administered 
bicarbonate to 10 patients and withheld it from 11 with similar degrees of 
DKA (pH  6.9  to  7.14).  No  significant difference  was observed 
between the treatment and control groups, with regard to changes  in  
glucose, ketone bodies, bicarbonate, or  blood pH.  Joslin56  was one of  
the  first to recognize the pitfalls of bicarbonate therapy. Joslin’s 
avoidance of bicarbonate therapy may have contributed to the decreased 
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mortality seen in his treatment protocol compared with other major 
clinical centres. When studied in a randomized prospective manner, there 
is no benefit to bicarbonate therapy in patients with a  pH between 6.9 
and 7.14.  The group reported with pH less than7 have been very small, 
however, and there have been  no  prospective randomized studies 
evaluating the use of  bicarbonate when the arterial pH  is  less than 6.9. 
Bicarbonate therapy is reserved for those patients with clinical 
manifestations of academia or a pH less than 757 . Usually 1 to 2 ampules 
of  sodium bicarbonate (50- 100 mEq) is added to a litre of  half normal 
saline to  make  a  nearly  isotonic  solution,  which  is  administered  over  
a  period  of 1-2 hours hours. If potassium is also low, 10- 20 mEq of  
potassium  chloride  may  be added. The venous pH  should  be  re- 
checked 30  minutes after administration and treatment repeated if the 
corrected pH is below  7. 
METABOLIC PROBLEMS DUE TO BICARBONATE 
ADMINISTRATION46 
1. Exacerbations of intracellular  acidosis 
2. Paradoxical acidosis of cerebrospinal  fluid 
3. Hypokalemia 
4. Adverse effect on oxy- haemoglobin dissociation curve 
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5. Impaired myocardial contractility 
6. Accentuation of ketogenesis and lactate  generation 
7. Oxidation of ketone anions during treatment generates equimolar 
amount of bicarbonate ions. 
8. Increased excretion of ketone bodies through kidneys and   lungs 
PHOSPHATE SUPPLEMENTATION : 
In 1950, Guest58 and Rapoport reported on the occurrence of 
hyperphosphatemia and the depletion of 2,3 diphosphoglycerate (2,3 
DPG)  during therapy for DKA . Since that time many treatment 
regimens have  included phosphate therapy. In the 1960s Benesch and 
Benesch59 and Chametin and Cornish60 independently reported studies on 
the modulation of hemoglobin oxygen affinity to 2,3-  DPG.   When 2,3  
–  DPG is depleted in erythrocytes,  the oxy- haemoglobin dissociation 
curve is shifted to the left, an effect counterbalanced by acidosis. 
Prior uncontrolled studies suggested that phosphate replacement 
during treatment of DKA was associated with improved mental status 
examination or decreased mortality. The majority of controlled and  
randomized  studies  however, have been unable to demonstrate clinical 
benefits of the routine use of phosphate replacement in DKA61 . 
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Enhanced urinary phosphate excretion in DKA commonly leads to 
hypophosphataemia. Complications related to hypophosphataemia are  
rare unless the condition is severe (phosphate <0.35 mmol/l) but include 
respiratory and skeletal muscle weakness, haemolytic anaemia,  and  
reduced  cardiac systolic function. Routine phosphate replacement has not 
been shown to be clinically beneficial68 and so replacement should only 
be considered  in  those with anaemia, cardiac dysfunction or respiratory 
depression and hypophosphataemia, or those with severe 
hypophosphataemia.  
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METHODOLOGY 
 
 SOURCE OF THE DATA 
Patients at Coimbatore Medical College and Hospital, who fulfil 
the inclusion and exclusion criteria will be taken up for the study after 
obtaining a written and informed consent. Demographic data, history and 
details of investigations done will be recorded in the study proforma. 
 METHODS OF COLLECTION OF DATA 
Study Type: Cross sectional Study. 
Duration of Study:One year. 
Sample Size : 200 patients 
INCLUSION CRITERIA:   
Diabetic patients with blood sugars >250mg/dL, with suspected 
diabetic ketoacidosis 
EXCLUSION CRITERIA: 
1.  Starvation ketoacidosis 
2. Alcoholic ketoacidosis 
3.  Salicylate poisoning 
4. Pregnant patients 
 
 
47  
Beta-hydroxybutyrate levels in capillary blood and acetoacetate in 
urine will be measured for each patient. 
Arterial blood gas analysis will be done to prove ketoacidotic state 
of the patient. Correlation between the two methods of measurement of 
ketone bodies and arterial blood gas values will be done 
 Investigations Required: 
1. Random blood sugar to be measured 
2. Urine Ketone body by Nitroprusside test 
3. Capillary beta hydroxybutyrate by Ketometer 
4. Arterial Blood Gas Analysis 
5. Serum electrolytes 
6. Complete hemogram 
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RESULTS 
Table 9: Distribution of Type 1 and Type 2 diabetes mellitus  
 
TYPE OF DM NO OF PATIENTS PERCENTAGE 
TYPE I 38 19% 
TYPE II 162 81% 
 
 
 
 
 
           Out of 200 cases, 162 were classified as type 2 diabetes mellitus 
(81%) and 38 were as type 1  diabetes mellitus   (9%). 
 
  
TYPE I, 38
TYPE II, 162
GRAPH 1 -TYPE OF DIABETES
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Table 10: Distribution of Patients according to   Sex 
 
SEX NO OF PATIENTS PERCENTAGE 
MALE 86 43% 
FEMALE 114 57% 
 
 
 
 
Out of 200 patients, 86 were male (43%) and 114 were female (57%).  
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4
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GRAPH 2-SEX DISTRIBUTION
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Table 11: Distribution of Patients according to  Age 
 
AGE NO OF PATIENTS PERCENTAGE 
<30 36 18% 
31-40 52 26% 
41-50 58 29% 
51-60 36 18% 
>60 18 9% 
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Table 12: Distribution of patients according to the duration of 
diabetes  
DURATION OF DM NO OF PATIENTS PERCENTAGE 
< 1 YR 56 28% 
1-5 YR 36 18% 
6-10 YR 64 32% 
> 10 YR 44 22% 
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Table 13:  Distribution of patients according to Treatment   History 
 
TREATMENT NO OF PATIENTS PERCENTAGE 
OHA ALONE 126 64% 
INSULIN ALONE 46 23% 
OHA+INSULIN 28 14% 
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Table 14:  Distribution of patients according to Clinical profile 
 
CLINICAL PROFILE NO OF PATIENTS PERCENTAGE 
VOMITTING 114 57% 
ABDOMINAL PAIN 52 26% 
DEHYDRATION 148 74% 
ACIDOTIC BREATHING 84 42% 
ALTERED SENSORIUM 24 12% 
FEVER 72 36% 
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Table 15:  Distribution of patients according to Urine ketone 
 
URINE KETONE NO OF PATIENTS PERCENTAGE 
PRESENT 72 36% 
ABSENT 128 64% 
 
 
 
 
 
Out of 200 patients,36% were positive for urine ketone. 
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Table 16:  Distribution of patients according to grading of Urine 
ketones 
 
URINE KETONE NO OF PATIENTS PERCENTAGE 
NIL 128 64% 
TRACE 18 9% 
1+ 10 5% 
2+ 14 7% 
3+ 30 15% 
 
 
 
 
In 81 % of the patients,Urine ketone was nil,15% with 3+ketonuria ,9% 
with trace amount of urine ketone ,7% with 2+ ketonuria . 
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Table 17:  Distribution of patients according to Blood ketone 
 
BLOOD KETONE NO OF PATIENTS PERCENTAGE 
POSITIVE 86 43% 
NEGATIVE 114 57% 
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Table 18: Distribution of patients according to grading of Blood 
ketone 
 
CAPILLARY BLOOD 
KETONE 
NO OF PATIENTS PERCENTAGE 
0-0.5 114 57% 
0.6-1.5 16 8% 
1.6-3.0 32 16% 
> 3.0 38 19% 
 
In our study 19% of the patients  the capillary blood ketone levels 
were >3.0 mmol/l,  1.6 to 3.0 mmol/l in  16% of the patients,0.6 to 1.5 
mmol/l in 8%  and 0-0.5 in 57 % of the patients. 
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Table 19:  Distribution of patients according to Random Blood Sugar 
 
BLOOD GLUCOSE NO OF PATIENTS PERCENTAGE 
MORE THAN 350 92 46% 
LESS THAN 350 108 54% 
 
 
 
 
In 46% of the patients ,the random blood sugar was more than 350 mgs/dl 
. 
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Table 20:  Distribution of patients according to Blood PH 
 
BLOOD PH NO OF PATIENTS PERCENTAGE 
LESS THAN 7.3 68 34% 
MORE THAN 7.3 132 76% 
 
 
 
 
 
76% of the patients blood PH was more than 7.30 ,and in 34% of 
the patients it was under 7.30. 
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Table 21:  Distribution of patients according to Bicarbonate 
 
 
BICARBONATE NO OF PATIENTS PERCENTAGE 
< 18 MEQ 56 28% 
> 18 MEQ 144 72% 
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Table 22:  Distribution of patients according to Diabetic Ketoacidosis 
 
DIABETIC 
KETOACIDOSIS 
NO OF PATIENTS PERCENTAGE 
PRESENT 46 23% 
ABSENT 154 77% 
 
 
 
 
 
Out of 200 patients, 46 patients (23%) were found to have Diabetic 
KetoAcidosis. 
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Table 23:  Mean and Standard Deviation of Capillary Blood ketone 
in DKA patients 
DIABETIC KETO 
ACIDOSIS 
CAPILLARY BLOOD KETONE 
MEAN SD 
PRESENT 4.1 1.2 
ABSENT 0.68 0.35 
   P VALUE - 0.002 
SIGNIFICANT 
UNPAIRED T TEST 
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Table 24:  Mean and Standard Deviation of Age (years) in DKA 
patients 
DIABETIC KETO 
ACIDOSIS 
AGE IN YEARS 
MEAN SD 
PRESENT 38.73 15.58 
ABSENT 43.24 11.16 
   P VALUE - 0.002 
SIGNIFICANT 
UNPAIRED T TEST 
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Table 25:  Mean and Standard Deviation of Random Blood Sugar in 
DKA patients 
DIABETIC KETO 
ACIDOSIS 
RANDOM BLOOD SUGAR 
MEAN SD 
PRESENT 385.13 59.46 
ABSENT 335.55 56.78 
   P VALUE - 0.001 
SIGNIFICANT 
UNPAIRED T TEST 
 
 Random blood sugar in DKA patients was 385.13+59.46 
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Table 26:  Mean and Standard Deviation of Blood PH in DKA 
patients 
 
DIABETIC KETO 
ACIDOSIS 
BLOOD PH 
MEAN SD 
PRESENT 7.21 0.5 
ABSENT 7.36 0.5 
   P VALUE - 0.001 
SIGNIFICANT 
UNPAIRED T TEST 
 
Mean blood ph in DKA patients is 7.21 + 0.5 
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Table 27:  Mean and Standard Deviation of Bicarbonate in DKA 
patients 
 
DIABETIC KETO ACIDOSIS 
BICARBONATE 
MEAN SD 
PRESENT 14.39 2.1 
ABSENT 23.37 2.96 
   P VALUE - 0.002 
SIGNIFICANT 
UNPAIRED T TEST 
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Table 28:  Mean and Standard Deviation of Capillary blood ketone 
according to RBS  
RANDOM BLOOD SUGAR 
CAPILLARY BLOOD KETONE 
MEAN SD 
> 350 2.07 2 
< 350 0.95 1.34 
   P VALUE - 0.001 
SIGNIFICANT 
UNPAIRED T TEST 
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Table 29:  Mean and Standard Deviation of Blood Ketone  
based on blood PH  
PH 
CAPILLARY BLOOD KETONE 
MEAN SD 
< 7.3 3.27 1.7 
> 7.3 0.53 0.82 
   P VALUE - 0.001 
SIGNIFICANT 
UNPAIRED T TEST 
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Table 30:  Mean and Standard Deviation of Blood ketone based on 
Bicarbonate  
 
BICARBONATE 
CAPILLARY BLOOD KETONE 
MEAN SD 
< 18 MEQ 3.59 1.59 
> 18 MEQ 0.64 0.95 
   P VALUE - 0.002 
SIGNIFICANT 
UNPAIRED T TEST 
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Table 31:  Comparison of Urine Ketone and Random Blood Sugar 
RANDOM BLOOD SUGAR 
URINE KETONE 
PRESENT ABSENT 
MORE THAN 350 48 44 
LESS THAN 350 24 84 
   P VALUE - 0.001 
SIGNIFICANT 
ODDS RATIO - 3.81 
CHI SQUARE TEST 
 
 In patients with RBS >350 mgs/dl ,48 patients presented with urine 
ketonuria, and in blood sugar <350 mgs/dl 24 patients presented with 
urine ketonuria. 
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Table 32:  Comparison of Blood Ketone and Random Blood Sugar 
RANDOM BLOOD SUGAR 
BLOOD KETONE 
PRESENT ABSENT 
MORE THAN 350 52 40 
LESS THAN 350 35 73 
   P VALUE - 0.001 
SIGNIFICANT 
ODDS RATIO - 2.71 
CHI SQUARE TEST 
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Table 33:  Comparison of Urine Ketone and Blood PH 
BLOOD PH 
URINE KETONE 
PRESENT ABSENT 
LESS THAN 7.3 54 14 
MORE THAN 7.3 18 114 
   P VALUE - 0.001 
SIGNIFICANT 
ODDS RATIO - 24 
CHI SQUARE TEST 
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Table 34:  Comparison of Blood Ketone and Blood Ph 
BLOOD PH 
BLOOD KETONE 
PRESENT ABSENT 
LESS THAN 7.3 60 8 
MORE THAN 7.3 27 105 
   P VALUE - 0.001 
SIGNIFICANT 
ODDS RATIO - 27 
CHI SQUARE TEST 
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Table 35:  Comparison of Urine Ketone and Bicarbonate 
BICARBONATE 
URINE KETONE 
PRESENT ABSENT 
LESS THAN 18 MEQ 48 8 
MORE THAN 18 MEQ 24 120 
   P VALUE - 0.001 
SIGNIFICANT 
ODDS RATIO - 30 
CHI SQUARE TEST 
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Table 36:  Comparison of Blood Ketone and Bicarbonate 
BICARBONATE 
BLOOD KETONE 
PRESENT ABSENT 
LESS THAN 18 MEQ 52 4 
MORE THAN 18 MEQ 35 109 
   P VALUE - 0.001 
SIGNIFICANT 
ODDS RATIO - 40 
CHI SQUARE TEST 
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    Table 37: Urine Ketone results based on Random blood sugar 
 
URINE KETONE 
RANDOM BLOOD SUGAR 
> 350 < 350 
NIL 44 84 
TRACE 8 10 
1+ 8 2 
2+ 8 6 
3+ 24 6 
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Table 38: Blood Ketone results based on Random blood sugar 
BLOOD KETONE 
RANDOM BLOOD SUGAR 
>350 < 350 
0-0.5 40 74 
0.6-1.5 4 12 
1.5-3.0 22 10 
> 3.0 26 12 
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Table 39:  Comparison of Urine Ketone and Blood PH 
URINE KETONE 
BLOOD PH 
< 7.3 > 7.3 
NIL 14 114 
TRACE 8 10 
1+ 6 4 
2+ 10 4 
3+ 30 0 
 
 
 
 
  
11%
44%
60%
71%
100%89%
56%
40%
29%
0%
0%
20%
40%
60%
80%
100%
120%
N I L T R A C E 1 + 2 + 3 +
GRAPH 31-URINE KETONE VS PH
< 7.3 > 7.3
 
 
79  
Table 40:  Comparison of Blood Ketone and PH 
BLOOD KETONE 
BLOOD PH 
< 7.3     >7.3 
0-0.5 8 106 
0.6-1.5 0 16 
1.5-3.0 28 4 
> 3.0 32 6 
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Table 41:  Comparison of Urine Ketone and Bicarbonate 
URINE KETONE 
BICARBONATE 
< 18 MEQ > 18 MEQ 
NIL 8 120 
TRACE 6 12 
1+ 4 6 
2+ 8 6 
3+ 30 0 
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 Table 42:  Comparison of Blood Ketone and Bicarbonate 
BLOOD KETONE 
BICARBONATE 
< 18 MEQ > 18 MEQ 
0-0.5 4 110 
0.6-1.5 0 16 
1.5-3.0 22 10 
> 3.0 30 8 
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Table 43:  Urine ketone results among DKA patients 
URINE KETONE 
DIABAETIC KETOACIDOSIS 
PRESENT ABSENT 
POSITIVE 42 30 
NEGATIVE 4 124 
 
 
 
 
URINE KETONE 
SENSITIVITY 91.30% 
SPECIFICITY 80.52% 
POSITIVE PREDICITVE VALUE 50.33% 
NEGATIVE PREDICITVE VALUE 96.88% 
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Table 44:  Blood ketone results among DKA patients 
BLOOD KETONE 
DIABAETIC KETOACIDOSIS 
PRESENT ABSENT 
POSITIVE 46 40 
NEGATIVE 0 114 
 
 
 
 
BLOOD KETONE 
SENSITIVITY 100.00% 
SPECIFICITY 84.03% 
POSITIVE PREDICITVE VALUE 53.49% 
NEGATIVE PREDICITVE VALUE 100.00% 
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Table45 :  Comparison of Urine Ketone and Blood ketone  
 
URINE 
KETONE 
BLOOD 
KETONE 
SENSITIVITY 91.30% 100.00% 
SPECIFICITY 80.52% 84.03% 
POSITIVE PREDICITVE 
VALUE 
50.33% 53.49% 
NEGATIVE PREDICITVE 
VALUE 
96.88% 100.00% 
 
Graph 37 :  Comparison of Urine Ketone and Blood ketone 
statistically
 
In our study ,Capillary blood ketones are statistically significant in 
terms of sensitivity, specificity, positive and negative predictive value. 
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DISCUSSION 
In our study our basic objective is to compare blood Beta -
hydroxybutyrate with urine acetoactate in diagnosis of DKA in 
emergency settings . Among the 200 patients with blood glucose > 250 
mgs / dl,who were included in the study, 81% (162 patients ) were type 2 
diabetics, 19% (38 patients ) were type 1 diabetics.57% (114 patients) 
were females and 43% (86 patients) were males. 
Mean age of the patients with diabeticketoacidosis is 38.73 + 15.58 
.Majority of the patients 55% were under the agegroup of 30 - 50 years. 
64% of the patients were under OHA alone ,23% of the patients were on 
Insulin and 19% on both .  
Most common clinical presentation was dehydration (74% ) , 
followed by vomiting (57%) and acidotic breathing (42% ). 
36%(72) of the patients had urine acetone positive, of which 15% 
(30) patients had 3+ ketonuria. 43% (86 patients ) were positive for blood 
ketone, of which 19% (38 patients) had > 3 mmol/l blood ketonemia. 
23%(46 patients) were diagnosed as diabetic ketoacidosis 
according to ADA criteria. 
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There were no urine ketones found in 128 cases .In 18 patients who 
didnot have ketonuria,capilllary blood ketones was determined to be 
positive (>0.5 mmol/l) .2 patients were severely ketonemic ,6 were 
moderately ketonemic, and 10 were mildly ketonemic.Of 128 patients 
with negative urine ketonuria ,2 were found positive for DKA according 
to ADA criteria. 
In a study by Prasanth et al63, it was shown that Beta-
hydroxybutyrate measurement in capillary blood is faster, more effective 
and a reliable method for the diagnosis of ketoacidosis in the Emergency 
Department setting.Sensitivity was found to be 88% and specificity was 
found to be 79% for this method in their study. 
Taboulet P et al64 in their study of 355 patients with random 
glucose above 250mg/dL, concluded that the measurement of 3-
betahydroxybutyrate in the capillary blood is faster and more effective 
than the use of dipsticks in the urine to detect ketoacidosis in the 
emergency department setting. 
Bektas et al65 found the sensitivity and specificity of urine ketone 
dipstick testing and capillary blood ketone testing in determining DKA 
were 66% and 78%, and 72% and 82%, respectively. 
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In our study, Sensitivity, specificity, positive and negative 
predictive value of urine ketone and capillary blood ketone in 
determining DKA were 91.30% ,80.52% ,50.33% ,96.88% and 100% 
,84.03% ,53.49% ,100% respectively 
The literature and the ADA encourage serum ketone measurement 
instead of urine dipstick tests because the specificity of urine dipsticks is 
low (<50%), and urine dipsticks frequently give false positive results, 
which cause an increased workload and inappropriate treatment. 
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CONCLUSION 
 
Diabetic ketoacidosis is a medical emergency and early 
identification helps to decrease mortality.As per our study 
outcome,sensitivity , specificity, positive and negative predictive value of 
capillary Beta - hydroxybutyrate measurement  are better compared to 
urine acetoacetate measurement.  
                 Capillary Beta - hydroxybutyrate measurement  also has the 
advantages of 
 Providing quick and quantitative results  
 Easy to use 
 Repeatability in emergency department 
To conclude ,Capillary beta - hydroxybutyrate measurement in 
triage is likely to decrease delays in recognition of DKA than routinely 
used urine dipstick for acetoacetate. 
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ANNEXURE –  I 
PROFORMA 
 
Name: I.P. No.: 
Address 
Date of Admission: Occupation: 
Date of Discharge: Final Diagnosis:  
 
HISTORY: 
A. Vomiting 
B. Abdominal pain 
C. Breathlessness 
D. Fever 
E. Altered sensorium 
F. Cough with expectoration 
G.  Burning micturition  
 
       H) Other PAST HISTORY: 
History of diabetes –  since 
Any major illness in the past 
Similar history in the past 
       History of I.H.D./ Hypertension  
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TREATMENT HISTORY: 
Treatment with insulin: Type 
 Dose Duration 
Oral antidiabetic drugs: Type 
 Dose Duration 
H/O omission of injections Drugs Insulin  
  Antidiabetic drugs 
FAMILY HISTORY: 
H/o Diabetes mellitus in the family H/o hypertension in the family 
PERSONAL HISTORY: 
Diet Appetite 
                  Bowels                                                 
            Smoking     Alcohol 
GENERAL PHYSICAL EXAMINATION: 
1. Appearance: 
2. Eyes 
3. Skin - Xanthomatous 
Nodules Dehydration 
4. Vital Signs  Signs of Dehydration: 
P.R. 
B.P. 
R.R. 
Temp. 
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5. Pedal oedema: 
6. Weight: 
7. Pigmentation: 
8. Oral cavity 
EXAMINATION OF CNS: 
Mental state – Conscious/ Unconscious / Drowsy/ Stupor Emotional state 
Gait,     Appearance and behaviour Orientation to time,  
place and time Speech     Skull and spine   Cranial nerves  
Motor System: Nutrition:     Tone:    Power: 
Co- ordination:        Abnormal movements:  
Tendon reflexes:      Superficial reflexes:          Plantar response:  
Sensory system:  
Respiratory System: Inspection   Palpation:    Percussion:   Auscultation: 
Cardiovascular System: 
Pulse: 
Radial: Rate Rhythm Volume Character 
Carotid Right Left Femoral 
Popliteal Posterior Dorsalis pedis 
B.P.: 
Inspection: Palpation: Percussion: 
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Perabdomen: 
Inspection  
Palpation 
 Percussion  
Auscultation  
INVESTIGATIONS: 
Hb% TC 
Differential count:  
E.S.R. 
Urine Sugar Albumin 
Urine: Culture and sensitivity  
Urine ketone bodies: 
Capillary Blood ketones: 
 Biochemical Investigations: 
Blood sugar Blood urea 
Ser. Creatinine Ser. Na+ Ser.K. 
Ser HCO3  Anion gap 
Ser Cl 
X- ray chest: 
E.C.G.: 
ABG: 
 
  
 
 
103  
INFORMED CONSENT 
DEPARTMENT OF GENERAL MEDICINE 
COIMBATORE MEDICAL COLLEGE COIMBATORE 
 
Principal investigator : Dr. SUGUMAR.N  
Research guide : Dr. RAVEENDRAN.M 
Organisation :  Department of General Medicine. 
Informed consent : I have been invited to participate in the research 
project titled  COMPARISON OF URINE ACETOACETIC ACID  AND 
CAPILLARY BETA HYDROXYBUTYRATE IN DIAGNOSIS AND 
MANAGEMENT OF DIABETIC KETOACIDOSIS 
 
I understand it will be answering a set of questionnaire undergo physical 
examination investigates and appropriate treatment. I also give consent to 
utilise my personal details for the study purpose and can be contacted if 
necessary. 
 
I am aware that I have the right to withdraw any time which will not affect my 
medical care. 
 
Name of the participant 
Signature 
Date. 
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Privacy and Confidentiality 
Privacy of individuals will be respected and any information about you 
or provided by you during the study will be kept strictly confidential. 
 
Authorization to publish Results 
Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified. 
 
STATEMENT OF CONSENT 
I volunteer and consent to participate in this study. I have read the 
consent  or it has been read to me. The study has been fully explained to me, 
and I may ask questions at any time. 
 
------------------------------- ------------------------------- 
Signature /Left thumb impression               Date  
 
 
 
-------------------------------- -------------------------------- 
Signature of witness                                     Date 
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MASTER CHART 
 
S. 
NO NAME 
AGE 
(YRS) SEX 
RBS 
(mgs%) PH 
HCO3 
(mEq/L) 
URINE 
KETONE 
BLOOD 
KETONE 
(mmol/L) 
TYPE OF DIABETES 
DURATION OF 
DIABETES 
TREATMENT 
DETAILS CLINICAL FEATURES 
(YEARS)  FEVER DEHYDRATION 
ABD 
PAIN VOMITING 
ALTERED 
SENSORIUM 
ACIDOTIC 
BREATHING 
1 UMA 32 F 376 7.2 13 3+ 2.9 TYPE  2 DIABETES 0.5 I+D      
2 BABU 44 M 268 7.14 11 TRACE 2.2 TYPE  2 DIABETES 1 D      
3 RANGASAMY 61 M 396 7.35 22 1+ 0.8 TYPE 2 DIABETES 12 D      
4 SINDHU 23 F 282 7.32 19 TRACE 3.2 TYPE 1 DIABETES 2 I      
5 KAMATCHI 43 F 368 7.45 24 NIL 0 TYPE 2 DIABETES 7 D      
6 MUTHU 38 M 412 7.16 17 TRACE 1.8 TYPE 2 DIABETES 2 D      
7 LAKSHMI 19 F 408 7.24 13 1+ 4.1 TYPE 1 DIABETES NEWLY DIAGNOSED I      
8 MUTHUSAMY 41 M 265 7.32 26 NIL 0.1 TYPE 2 DIABETES 6 D      
9 SOMASUNTHIRAM 52 M 452 7.28 15 3+ 4.6 TYPE 2 DIABETES 13 I      
10 SOWMIYA 21 F 372 7.28 15 3+ 3.5 TYPE 1 DIABETES 5 I      
11 SUGANTHI 42 F 276 7.41 24 NIL 0.2 TYPE 2 DIABETES 1 D      
12 NAGARAJ 33 M 345 7.16 15 2+ 2.5 TYPE 2 DIABETES NEWLY DIAGNOSED D      
13 RANGAMMAL 64 F 298 7.35 24 NIL 1.2 TYPE 2 DIABETES 20 D      
14 MANI 26 M 472 7.23 17 3+ 2.8 TYPE 1 DIABETES 0.5 I      
15 KANCHANA 47 F 310 7.43 27 NIL 0.3 TYPE 2 DIABETES 6 D      
16 JOTHI 35 F 379 7.45 22 NIL 0.2 TYPE 2 DIABETES 0.5 D      
17 KANNAMMAL 67 F 368 7.24 12 3+ 5.2 TYPE 2 DIABETES 13 D      
18 SURESH 31 M 423 7.42 23 NIL 0.4 TYPE 2 DIABETES 0.5 I+D      
19 KARTHI 36 M 446 7.28 16 2+ 1.9 TYPE 2 DIABETES 3 D      
20 JOTHIYAMMAL 61 F 323 7.22 15 NIL 3.6 TYPE 2 DIABETES 14 I+D      
21 SANTHIYA 18 F 298 7.32 19 NIL 1.5 TYPE 1 DIABETES 0.5 I      
22 RAJAMMAL 54 F 334 7.25 15 NIL 2.5 TYPE 2 DIABETES 11 D      
23 PAPATHI 37 F 412 7.41 24 NIL 0.2 TYPE 2 DIABETES 1 D      
24 RAMESH 27 M 506 7.3 17 3+ 4.8 TYPE 1 DIABETES 1 I      
25 BALASUBRAMANIYAM 43 M 312 7.4 26 NIL 1.1 TYPE 2 DIABETES 7 I+D      
26 DEVI 40 F 356 7.3 24 TRACE 2.9 TYPE 2 DIABETES 6 D      
27 RATHINAM 45 F 322 7.38 26 NIL 0.4 TYPE 2 DIABETES 4 I+D      
28 MURALI 33 M 402 7.29 24 1+ 1.7 TYPE 2 DIABETES 1 D      
29 GOVINTHARAJ 69 M 298 7.15 14 3+ 5.7 TYPE 2 DIABETES 13 D      
30 DEVAGI 35 F 316 7.36 25 NIL 0.3 TYPE 2 DIABETES 1 D      
31 SATHIYA 29 F 432 7.25 16 1+ 4.4 TYPE 1 DIABETES 1 I      
32 GANAPATHY 45 M 376 7.4 24 TRACE 0.2 TYPE 2 DIABETES 6 D      
33 SUBBU GR 55 M 282 7.38 22 NIL 0.8 TYPE 2 DIABETES 10 I+D      
34 BALASUGANTHI 37 F 306 7.42 22 NIL 0.2 TYPE 2 DIABETES 0.5 D      
35 LAKSHMANAN 42 M 438 7.12 18 2+ 2.8 TYPE 2 DIABETES 8 D      
 
 
107  
36 SAROJINI 47 F 398 7.35 28 NIL 0.5 TYPE 2 DIABETES 6 I+D      
37 KARTHIKEYAN 25 M 274 7.34 24 TRACE 0.9 TYPE 1 DIABETES 4 I      
38 NAGAMANI 42 F 280 7.38 24 NIL 0.1 TYPE 2 DIABETES 7 D      
39 SANTHOSH 29 M 289 7.19 12 2+ 2.8 TYPE 1 DIABETES 3 I      
40 MARIYAMMAL 43 F 316 7.4 26 NIL 0.1 TYPE 2 DIABETES 6 D      
41 ESHWARI 32 F 390 7.28 21 NIL 1.8 TYPE 2 DIABETES 1 D      
42 SUSILA 41 F 310 7.4 23 NIL 0.1 TYPE 2 DIABETES 6 D      
43 THULASI 47 F 446 7.18 12 3+ 6.1 TYPE 2 DIABETES 7 I      
44 VELUMANI 33 F 318 7.35 22 NIL 0.2 TYPE 2 DIABETES 1 D      
45 RAMANATHAN 38 M 298 7.42 24 NIL 0.4 TYPE 2 DIABETES 0.5 D      
46 BALAJI 24 M 316 7.22 11 3+ 4.3 TYPE 1 DIABETES NEWLY DIAGNOSED I      
47 VISALAKSHI 43 F 358 7.38 25 NIL 0.4 TYPE 2 DIABETES 6 I+D      
48 SIVAGAMI 37 F 276 7.36 28 NIL 0.1 TYPE 2 DIABETES 1 D      
49 KARUPPUSAMY 58 M 297 7.22 16 3+ 3 TYPE 2 DIABETES 9 D      
50 RANJITH 31 M 306 7.42 26 NIL 0.2 TYPE 2 DIABETES 0.5 D      
51 MARAGATHAM 59 F 411 7.38 25 NIL 0.2 TYPE 2 DIABETES 11 D      
52 JAGAN 32 M 301 7.4 23 NIL 0.1 TYPE 2 DIABETES 1 D      
53 NALINI 47 F 421 7.28 18 NIL 0.4 TYPE 2 DIABETES 8 D      
54 KANDHASAMY 35 M 311 7.36 25 TRACE 0.3 TYPE 2 DIABETES 1 D      
55 MUTHAMMAL 61 F 413 7.39 24 NIL 0.2 TYPE 2 DIABETES 14 D      
56 THIRUMURUGAN 41 M 322 7.35 27 NIL 0.5 TYPE 2 DIABETES 2 I+D      
57 NAVIN 21 M 412 7.28 17 3+ 4.9 TYPE 1 DIABETES 4 I      
58 SUBRAMANI 63 M 378 7.43 26 NIL 0.1 TYPE 2 DIABETES 9 D      
59 CHITHRA 23 F 352 7.21 13 3+ 5.2 TYPE 1 DIABETES NEWLY DIAGNOSED I      
60 MURUGAN 60 M 298 7.42 24 NIL 0.1 TYPE 2 DIABETES 12 D      
61 PAVITHRA 38 F 277 7.23 25 NIL 0 TYPE 2 DIABETES 1 D      
62 CHINNAMMMAL 65 F 263 7.4 25 NIL 0.2 TYPE 2 DIABETES 14 I+D      
63 BALAKRISHNAN 52 M 398 7.34 21 NIL 2 TYPE 2 DIABETES 12 D      
64 PALANISAMY 48 M 278 7.38 26 NIL 0.3 TYPE 2 DIABETES 7 D      
65 RANGASAMY 51 M 258 7.34 22 NIL 0.3 TYPE 2 DIABETES 8 D      
66 PUNITHA 28 F 264 7.34 19 2+ 3.7 TYPE 1 DIABETES 5 I      
67 KUPPUSAMY 69 M 389 7.42 24 NIL 0.3 TYPE 2 DIABETES 16 D      
68 RANGANAYAGI 36 F 352 7.35 22 NIL 0.2 TYPE 2 DIABETES 1 D      
69 DURAISAMY 54 M 467 7.38 26 NIL 0.2 TYPE 2 DIABETES 11 I      
70 LATHA 47 F 272 7.26 26 NIL 0.1 TYPE 2 DIABETES 9 D      
71 KRISHNAN 37 M 376 7.23 15 3+ 3 TYPE 2 DIABETES NEWLY DIAGNOSED D      
72 AARIFA 57 F 316 7.43 23 NIL 0.1 TYPE 2 DIABETES 10 D      
73 VENI 39 F 328 7.42 23 NIL 0.2 TYPE 2 DIABETES 2 I+D      
74 MANI 43 M 362 7.42 21 NIL 0.2 TYPE 2 DIABETES 6 D      
75 MUTHU 51 M 306 7.38 24 NIL 0.1 TYPE 2 DIABETES 7 I+D      
76 CHANTHIRA 44 F 392 7.12 11 3+ 6.2 TYPE 2 DIABETES 6 D      
77 VIJAYA 26 F 416 7.28 17 TRACE 3.6 TYPE 1 DIABETES 1 I      
78 PALANAL 43 F 296 7.4 22 NIL 0.2 TYPE 2 DIABETES 6 D      
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79 JEEVITHA 21 F 368 7.41 28 NIL 1.2 TYPE 1 DIABETES 5 I      
80 SOMU 42 M 288 7.4 23 NIL 0.2 TYPE 2 DIABETES 6 D      
81 AKKAMMAL 58 F 356 7.39 24 NIL 0.2 TYPE 2 DIABETES 11 D      
82 MANICKAM 46 M 272 7.33 25 NIL 0.3 TYPE 2 DIABETES 6 D      
83 SUBHA 25 F 539 7.3 19 2+ 4.1 TYPE 1 DIABETES NEWLY DIAGNOSED I      
84 KUMARESHWARI 59 F 277 7.41 24 NIL 0.4 TYPE 2 DIABETES 10 I+D      
85 SARGUNAM 46 F 290 7.38 24 NIL 0.2 TYPE 2 DIABETES 6 D      
86 SRIDEVI 44 F 326 7.3 22 NIL 0.3 TYPE 2 DIABETES 7 D      
87 PANIMALAR 31 F 339 7.32 20 1+ 3.7 TYPE 1 DIABETES 1 I      
88 PARAMESHWARAN 43 M 342 7.4 23 NIL 0.1 TYPE 2 DIABETES 6 D      
89 RANI 49 F 361 7.41 18 NIL 0 TYPE 2 DIABETES 7 D      
90 AMMASAI 54 F 300 7.39 26 NIL 0.1 TYPE 2 DIABETES 10 D      
91 VINOTH 26 M 362 7.31 20 2+ 2.8 TYPE 1 DIABETES 4 I      
92 LATHA 43 F 305 7.4 27 NIL 0.1 TYPE 2 DIABETES 6 D      
93 MURUGESHNAN 57 M 326 7.36 25 NIL 0.1 TYPE 2 DIABETES 10 D      
94 BAKKIYAM 51 F 438 7.14 12 3+ 5.8 TYPE 2 DIABETES 9 I      
95 PATHIMA 58 F 325 7.33 28 NIL 0.2 TYPE 2 DIABETES 11 D      
96 MURUGAN 48 M 402 7.36 26 NIL 0 TYPE 2 DIABETES 7 D      
97 VIJAYALAKSHMI 53 F 410 7.33 24 NIL 0.3 TYPE 2 DIABETES 10 I+D      
98 BANU 36 F 290 7.38 25 NIL 0.4 TYPE 2 DIABETES 1 D      
99 RAJESH 27 M 268 7.38 22 TRACE 1.5 TYPE 1 DIABETES 3 I      
100 PERIYASAMY 40 M 380 7.34 24 NIL 0.2 TYPE 2 DIABETES 4 D      
101 MUTHUMARI 37 F 412 7.41 24 NIL 0.2 TYPE 2 DIABETES 1 D      
102 BARATHAN 43 M 312 7.4 26 NIL 1.1 TYPE 2 DIABETES 7 I+D      
103 MANIGANDAN 45 M 376 7.4 24 TRACE 0.2 TYPE 2 DIABETES 6 D      
104 VELUMANI 54 F 300 7.39 26 NIL 0.1 TYPE 2 DIABETES 10 D      
105 SAROJA 43 F 305 7.4 27 NIL 0.1 TYPE 2 DIABETES 6 D      
106 SEETHA 21 F 372 7.28 15 3+ 3.5 TYPE 1 DIABETES 5 I      
107 THANGAVEL 57 M 326 7.36 25 NIL 0.1 TYPE 2 DIABETES 10 D      
108 SUNTHARI 54 F 334 7.25 15 NIL 2.5 TYPE 2 DIABETES 11 D      
109 SANJANA 23 F 352 7.21 13 3+ 5.2 TYPE 1 DIABETES NEWLY DIAGNOSED I      
110 PRASANA 26 M 362 7.31 20 2+ 2.8 TYPE 1 DIABETES 4 I      
111 PUSHPA 64 F 298 7.35 24 NIL 1.2 TYPE 2 DIABETES 20 D      
112 SELVI 51 F 438 7.14 12 3+ 5.8 TYPE 2 DIABETES 9 I      
113 AMSAVENI 58 F 325 7.33 28 NIL 0.2 TYPE 2 DIABETES 11 D      
114 MURUGAVEL 69 M 298 7.15 14 3+ 5.7 TYPE 2 DIABETES 13 D      
115 DEVASENAI 37 F 276 7.36 28 NIL 0.1 TYPE 2 DIABETES 1 D      
116 THANGAVEL 48 M 402 7.36 26 NIL 0 TYPE 2 DIABETES 7 D      
117 JOTHIMANI 53 F 410 7.33 24 NIL 0.3 TYPE 2 DIABETES 10 I+D      
118 MANIVASAGAM 44 M 268 7.14 11 TRACE 2.2 TYPE  2 DIABETES 1 D      
119 ABI 19 F 408 7.24 13 1+ 4.1 TYPE 1 DIABETES NEWLY DIAGNOSED I      
120 RAGU 33 M 345 7.16 15 2+ 2.5 TYPE 2 DIABETES NEWLY DIAGNOSED D      
121 KUMAR 25 M 274 7.34 24 TRACE 0.9 TYPE 1 DIABETES 4 I      
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122 PALANIYAPPAN 58 M 297 7.22 16 3+ 3 TYPE 2 DIABETES 9 D      
123 SANTHI 45 F 322 7.38 26 NIL 0.4 TYPE 2 DIABETES 4 I+D      
124 VIJAYA 47 F 398 7.35 28 NIL 0.5 TYPE 2 DIABETES 6 I+D      
125 MAHALAKSHMI 43 F 358 7.38 25 NIL 0.4 TYPE 2 DIABETES 6 I+D      
126 BALA 27 M 268 7.38 22 TRACE 1.5 TYPE 1 DIABETES 3 I      
127 DHANALAKSHMI 32 F 376 7.2 13 3+ 2.9 TYPE  2 DIABETES 0.5 I+D      
128 SHARMILA 18 F 298 7.32 19 NIL 1.5 TYPE 1 DIABETES 0.5 I      
129 DEVAKI 35 F 316 7.36 25 NIL 0.3 TYPE 2 DIABETES 1 D      
130 MANOJ 27 M 506 7.3 17 3+ 4.8 TYPE 1 DIABETES 1 I      
131 AMBUJAM 40 F 356 7.3 24 TRACE 2.9 TYPE 2 DIABETES 6 D      
132 THANABAKKIYAM 59 F 411 7.38 25 NIL 0.2 TYPE 2 DIABETES 11 D      
133 ESWARAN 31 M 306 7.42 26 NIL 0.2 TYPE 2 DIABETES 0.5 D      
134 PONNUSAMY 52 M 452 7.28 15 3+ 4.6 TYPE 2 DIABETES 13 I      
135 UMADEVI 41 F 310 7.4 23 NIL 0.1 TYPE 2 DIABETES 6 D      
136 MURUGAYAN 41 M 322 7.35 27 NIL 0.5 TYPE 2 DIABETES 2 I+D      
137 HARIHARAN 36 M 446 7.28 16 2+ 1.9 TYPE 2 DIABETES 3 D      
138 MALA 43 F 316 7.4 26 NIL 0.1 TYPE 2 DIABETES 6 D      
139 JAYA 47 F 446 7.18 12 3+ 6.1 TYPE 2 DIABETES 7 I      
140 SHANKAR 35 M 311 7.36 25 TRACE 0.3 TYPE 2 DIABETES 1 D      
141 ARUMUGAM 61 M 396 7.35 22 1+ 0.8 TYPE 2 DIABETES 12 D      
142 SANJAY 24 M 316 7.22 11 3+ 4.3 TYPE 1 DIABETES NEWLY DIAGNOSED I      
143 JEGANATHAN 40 M 380 7.34 24 NIL 0.2 TYPE 2 DIABETES 4 D      
144 ARUKKANI 65 F 263 7.4 25 NIL 0.2 TYPE 2 DIABETES 14 I+D      
145 SUBBULAKSHMI 43 F 296 7.4 22 NIL 0.2 TYPE 2 DIABETES 6 D      
146 VELUSAMY 69 M 389 7.42 24 NIL 0.3 TYPE 2 DIABETES 16 D      
147 AMMASAIAMMAL 67 F 368 7.24 12 3+ 5.2 TYPE 2 DIABETES 13 D      
148 SAKUNTHALA 39 F 328 7.42 23 NIL 0.2 TYPE 2 DIABETES 2 I+D      
149 JEEVABAHARATHI 23 F 282 7.32 19 TRACE 3.2 TYPE 1 DIABETES 2 I      
150 KARUPPANAN 63 M 378 7.43 26 NIL 0.1 TYPE 2 DIABETES 9 D      
151 RASATHI 61 F 323 7.22 15 NIL 3.6 TYPE 2 DIABETES 14 I+D      
152 RAMACHANDRAN 51 M 258 7.34 22 NIL 0.3 TYPE 2 DIABETES 8 D      
153 GOPAL 60 M 298 7.42 24 NIL 0.1 TYPE 2 DIABETES 12 D      
154 MURUGESAN 54 M 467 7.38 26 NIL 0.2 TYPE 2 DIABETES 11 I      
155 KUMUTHA 42 F 276 7.41 24 NIL 0.2 TYPE 2 DIABETES 1 D      
156 LOGU 48 M 278 7.38 26 NIL 0.3 TYPE 2 DIABETES 7 D      
157 BABY 57 F 316 7.43 23 NIL 0.1 TYPE 2 DIABETES 10 D      
158 MUHAMMED 51 M 306 7.38 24 NIL 0.1 TYPE 2 DIABETES 7 I+D      
159 AASHIQ 26 M 472 7.23 17 3+ 2.8 TYPE 1 DIABETES 0.5 I      
160 RADHAKRISHNAN 42 M 438 7.12 18 2+ 2.8 TYPE 2 DIABETES 8 D      
161 THENMOZHI 28 F 264 7.34 19 2+ 3.7 TYPE 1 DIABETES 5 I      
162 THENNARASAN 38 M 298 7.42 24 NIL 0.4 TYPE 2 DIABETES 0.5 D      
163 PRIYA 29 F 432 7.25 16 1+ 4.4 TYPE 1 DIABETES 1 I      
164 SARANYA 21 F 368 7.41 28 NIL 1.2 TYPE 1 DIABETES 5 I      
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165 CHELLAMMAL 59 F 277 7.41 24 NIL 0.4 TYPE 2 DIABETES 10 I+D      
166 RAMA LAKSHMI 31 F 339 7.32 20 1+ 3.7 TYPE 1 DIABETES 1 I      
167 NITHYANANTHAM 38 M 412 7.16 17 TRACE 1.8 TYPE 2 DIABETES 2 D      
168 VIJAY 31 M 423 7.42 23 NIL 0.4 TYPE 2 DIABETES 0.5 I+D      
169 PREMA 32 F 390 7.28 21 NIL 1.8 TYPE 2 DIABETES 1 D      
170 MEERA 61 F 413 7.39 24 NIL 0.2 TYPE 2 DIABETES 14 D      
171 VEDHANAYAGAM 52 M 398 7.34 21 NIL 2 TYPE 2 DIABETES 12 D      
172 SHEELA 47 F 310 7.43 27 NIL 0.3 TYPE 2 DIABETES 6 D      
173 RAJALAKSHMI 38 F 277 7.23 25 NIL 0 TYPE 2 DIABETES 1 D      
174 LALITHA 36 F 352 7.35 22 NIL 0.2 TYPE 2 DIABETES 1 D      
175 SOWMIYA 37 F 306 7.42 22 NIL 0.2 TYPE 2 DIABETES 0.5 D      
176 PRABHAKARAN 43 M 362 7.42 21 NIL 0.2 TYPE 2 DIABETES 6 D      
177 ANGAYI 58 F 356 7.39 24 NIL 0.2 TYPE 2 DIABETES 11 D      
178 GNANAMANI 46 F 290 7.38 24 NIL 0.2 TYPE 2 DIABETES 6 D      
179 ARUN KUMAR 29 M 289 7.19 12 2+ 2.8 TYPE 1 DIABETES 3 I      
180 DAMAYANTHI 44 F 392 7.12 11 3+ 6.2 TYPE 2 DIABETES 6 D      
181 KALAISELVAN 41 M 265 7.32 26 NIL 0.1 TYPE 2 DIABETES 6 D      
182 AANANDHAN 32 M 301 7.4 23 NIL 0.1 TYPE 2 DIABETES 1 D      
183 SASIKUMAR 46 M 272 7.33 25 NIL 0.3 TYPE 2 DIABETES 6 D      
184 SUMATHI 44 F 326 7.3 22 NIL 0.3 TYPE 2 DIABETES 7 D      
185 DHARMALINGAM 55 M 282 7.38 22 NIL 0.8 TYPE 2 DIABETES 10 I+D      
186 JANAKI 47 F 421 7.28 18 NIL 0.4 TYPE 2 DIABETES 8 D      
187 RAMALINGAM 42 M 288 7.4 23 NIL 0.2 TYPE 2 DIABETES 6 D      
188 RADHA 25 F 539 7.3 19 2+ 4.1 TYPE 1 DIABETES NEWLY DIAGNOSED I      
189 JEYALAKSHMI 43 F 368 7.45 24 NIL 0 TYPE 2 DIABETES 7 D      
190 UMAMAHESHWARI 42 F 280 7.38 24 NIL 0.1 TYPE 2 DIABETES 7 D      
191 MARRY 47 F 272 7.26 26 NIL 0.1 TYPE 2 DIABETES 9 D      
192 CHANDRASEKAR 43 M 342 7.4 23 NIL 0.1 TYPE 2 DIABETES 6 D      
193 KANAGAVALLI 49 F 361 7.41 18 NIL 0 TYPE 2 DIABETES 7 D      
194 PRAVEENA 26 F 416 7.28 17 TRACE 3.6 TYPE 1 DIABETES 1 I      
195 KAVITHA 35 F 379 7.45 22 NIL 0.2 TYPE 2 DIABETES 0.5 D      
196 NEELAKANDAN 33 M 402 7.29 24 1+ 1.7 TYPE 2 DIABETES 1 D      
197 CHELLAMA 33 F 318 7.35 22 NIL 0.2 TYPE 2 DIABETES 1 D      
198 CHANDRAN 21 M 412 7.28 17 3+ 4.9 TYPE 1 DIABETES 4 I      
199 ARJUNAN 37 M 376 7.23 15 3+ 3 TYPE 2 DIABETES NEWLY DIAGNOSED D      
200 SHARATHA 36 F 290 7.38 25 NIL 0.4 TYPE 2 DIABETES 1 D      
Abbreviations for Master Chart 
I - Insulin 
D- Drugs 
F - Female 
M – Male 
